COVID

Contributors to the COVID-19 microbiome study include (front row, from left) Julie Bastarache, MD, Meghan Shilts, MS, MHS, (middle row, from left) Jodell Jackson, PhD, Suman Das, PhD, Angela Jones, MS, (back row, from left) Jonathan Schmitz, PhD, MD, Simon Mallal, MBBS, and Jordan Best, PhD.
March 11, 2021

‘Friendly’ bacteria may impact COVID severity

The U.S. Centers for Disease Control and Prevention (CDC) has awarded Vanderbilt University Medical Center a two-year, $3.7-million contract to determine genetic and bacterial factors that may increase the risk for severe illness and death from COVID-19.

March 9, 2021

Pediatric emergency visits, hospitalizations down sharply during pandemic: study

Amid the COVID-19 pandemic, children’s hospitals across the United States have seen signification reductions in the number of children being treated for common pediatric illnesses like asthma and pneumonia, according to a new multicenter study led by Monroe Carell Jr. Children’s Hospital at Vanderbilt.

March 8, 2021

Infection Prevention team likens pandemic to an ultramarathon

“We always say that infection prevention is everyone’s business, and the pandemic reflects that.”

March 4, 2021

Monoclonal antibody “cocktail” blocks COVID-19 variants: study

A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.

March 4, 2021

COVID-19 survey data added to All of Us platform

In December 2020, the federal government’s massive precision medicine research initiative, All of Us (AoU), made available to qualified researchers initial results from its ongoing COVID-19 Participant Experience (COPE) Survey, as well as physical activity and heart rate data collected from Fitbit devices worn by AoU participants.

March 4, 2021

Biostatistician DeMets set for next Discovery Lecture

David DeMets, PhD, known for his work on statistical methods to monitor interim clinical trial data for early evidence of benefit or harm, will deliver the next web-based Discovery Lecture.